ES2739383T3 - Haptenos de paliperidona - Google Patents
Haptenos de paliperidona Download PDFInfo
- Publication number
- ES2739383T3 ES2739383T3 ES13753775T ES13753775T ES2739383T3 ES 2739383 T3 ES2739383 T3 ES 2739383T3 ES 13753775 T ES13753775 T ES 13753775T ES 13753775 T ES13753775 T ES 13753775T ES 2739383 T3 ES2739383 T3 ES 2739383T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- protein
- compound
- paliperidone
- hapten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(N(CC1)CCN1*=O)=O Chemical compound CC(N(CC1)CCN1*=O)=O 0.000 description 2
- SUHFJEFEVKONFS-UHFFFAOYSA-N CC(N=C1N2CCCC1OC(CCNC(CCN(C(C=C1)=O)C1=O)=O)=O)=C(CCN(CC1)CCC1c1n[o]c3c1ccc(F)c3)C2=O Chemical compound CC(N=C1N2CCCC1OC(CCNC(CCN(C(C=C1)=O)C1=O)=O)=O)=C(CCN(CC1)CCC1c1n[o]c3c1ccc(F)c3)C2=O SUHFJEFEVKONFS-UHFFFAOYSA-N 0.000 description 2
- ZOKLMNFWAUDGGA-UHFFFAOYSA-N CC(N=C1N2CCCC1OCCCCCC(N(CC1)CCN1C(CCC(O)=O)=O)=O)=C(CCN(CC1)CCC1c1n[o]c3cc(F)ccc13)C2=O Chemical compound CC(N=C1N2CCCC1OCCCCCC(N(CC1)CCN1C(CCC(O)=O)=O)=O)=C(CCN(CC1)CCC1c1n[o]c3cc(F)ccc13)C2=O ZOKLMNFWAUDGGA-UHFFFAOYSA-N 0.000 description 2
- CDZRGXIJEIWKRK-UHFFFAOYSA-N CC(N=C1N2CCCC1OCCCNC(CCN(C(C=C1)=O)C1=O)=O)=C(CCN(CC1)CCC1c1n[o]c3c1ccc(F)c3)C2=O Chemical compound CC(N=C1N2CCCC1OCCCNC(CCN(C(C=C1)=O)C1=O)=O)=C(CCN(CC1)CCC1c1n[o]c3c1ccc(F)c3)C2=O CDZRGXIJEIWKRK-UHFFFAOYSA-N 0.000 description 2
- RGEVIRBPZWWNPA-UHFFFAOYSA-N CC(N(CC1)CCN1C(C(C)(C)C)=O)O Chemical compound CC(N(CC1)CCN1C(C(C)(C)C)=O)O RGEVIRBPZWWNPA-UHFFFAOYSA-N 0.000 description 1
- NBQBICYRKOTWRR-UHFFFAOYSA-N CC(N(CC1)CCN1C(C)=O)=O Chemical compound CC(N(CC1)CCN1C(C)=O)=O NBQBICYRKOTWRR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691459P | 2012-08-21 | 2012-08-21 | |
| PCT/US2013/055712 WO2014031595A1 (en) | 2012-08-21 | 2013-08-20 | Haptens of paliperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2739383T3 true ES2739383T3 (es) | 2020-01-30 |
Family
ID=49081008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13753775T Active ES2739383T3 (es) | 2012-08-21 | 2013-08-20 | Haptenos de paliperidona |
| ES19177909T Active ES2971506T3 (es) | 2012-08-21 | 2013-08-20 | Haptenos de paliperidona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19177909T Active ES2971506T3 (es) | 2012-08-21 | 2013-08-20 | Haptenos de paliperidona |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9394354B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2888258B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6286429B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104837838A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013305930B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2882555C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2739383T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2888258T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2888258T (cg-RX-API-DMAC7.html) |
| TR (1) | TR201911272T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014031595A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013305901B2 (en) | 2012-08-21 | 2017-10-26 | Saladax Biomedical Inc. | Antibodies to olanzapine and use thereof |
| CN104736561B (zh) | 2012-08-21 | 2018-06-12 | 詹森药业有限公司 | 帕潘立酮的抗体及其用途 |
| ES2739383T3 (es) * | 2012-08-21 | 2020-01-30 | Janssen Pharmaceutica Nv | Haptenos de paliperidona |
| ES2822004T3 (es) | 2012-08-21 | 2021-04-28 | Janssen Pharmaceutica Nv | Anticuerpos contra quetiapina y uso de los mismos |
| JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールハプテンに対する抗体及びその使用 |
| JP2015529199A (ja) * | 2012-08-21 | 2015-10-05 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンハプテンに対する抗体及びその使用 |
| JP6450314B2 (ja) | 2012-08-21 | 2019-01-09 | ヤンセン ファーマシューティカ エヌ．ベー． | クエチアピンハプテンに対する抗体及びその使用 |
| WO2014031584A1 (en) | 2012-08-21 | 2014-02-27 | Janssen Pharmaceutica Nv | Haptens of aripiprazole and their use in immunoassays |
| CN107043424B (zh) | 2012-08-21 | 2021-03-16 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| AU2013305879B2 (en) | 2012-08-21 | 2017-10-12 | Saladax Biomedical Inc. | Antibodies to aripiprazole and use thereof |
| JP6389177B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | オランザピンハプテンに対する抗体及びその使用 |
| CN108517014A (zh) | 2012-08-21 | 2018-09-11 | 詹森药业有限公司 | 利培酮半抗原的抗体及其用途 |
| WO2017106508A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to quetiapine and use thereof |
| CA3008809A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
| CN111751535B (zh) * | 2020-07-02 | 2023-07-11 | 北京勤邦科技股份有限公司 | 一种检测硫丹的试纸条及其应用 |
| AU2021406283A1 (en) * | 2020-12-22 | 2023-06-22 | Intervet International B.V. | Conjugated zearalenone to protect against mycotoxicosis |
| CN116003404B (zh) * | 2022-12-14 | 2024-10-01 | 杭州同舟生物技术有限公司 | 一种利培酮人工半抗原、人工抗原及其制备方法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US5284948A (en) * | 1991-06-07 | 1994-02-08 | Eastman Kodak Company | Drug hapten analogues for immunoassays |
| NO305125B1 (no) | 1992-05-29 | 1999-04-06 | Lilly Industries Ltd | Farmas°ytiske forbindelser |
| US6034078A (en) | 1992-05-29 | 2000-03-07 | Eli Lilly And Company Limited | Thienobenzodiazepine compounds |
| US5395933A (en) | 1992-08-07 | 1995-03-07 | Eastman Kodak Company | Carbamazepine hapten analogues |
| US6958156B2 (en) | 2000-12-15 | 2005-10-25 | Vyrex Corporation | Isoflavone derivatives |
| US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| ES2358737T3 (es) * | 2002-01-31 | 2011-05-13 | Randox Laboratories Ltd. | Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos. |
| ES2297142T3 (es) | 2002-03-28 | 2008-05-01 | Eli Lilly And Company | Arilbenzodiazepinas sustituidas con piperazina y su uso como antagonistas del receptor de dopamina para el tratamiento de trastornos psicoticos. |
| AU2003264915A1 (en) | 2002-08-05 | 2004-02-25 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
| PT1664007E (pt) | 2003-09-23 | 2010-02-15 | Fermion Oy | Preparação de quetiapina |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| FR2878850B1 (fr) * | 2004-12-02 | 2008-10-31 | Cis Bio Internat Sa | Derives de l'inositol-1-phosphate |
| KR20100075455A (ko) | 2007-09-27 | 2010-07-02 | 노파르티스 아게 | 약물 모니터링 분석법 |
| US20100069356A1 (en) | 2008-09-17 | 2010-03-18 | Auspex Pharmaceuticals, Inc. | Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors |
| WO2010043893A1 (en) | 2008-10-14 | 2010-04-22 | Astrazeneca Ab | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections |
| EP2194048A1 (en) | 2008-12-02 | 2010-06-09 | Dirk Sartor | Nitrate esters for the treatment of vascular and metabolic diseases |
| HUE052816T2 (hu) | 2009-07-31 | 2021-05-28 | Ascendis Pharma As | Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek |
| US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| EP2343296A1 (en) | 2009-12-01 | 2011-07-13 | Chemo Ibérica, S.A. | A process for the purification of paliperidone |
| JP5544024B2 (ja) | 2009-12-31 | 2014-07-09 | ケムファーム・インコーポレーテッド | クエチアピンのアミノ酸結合体、その製造法及び使用法 |
| HUE042945T2 (hu) | 2010-03-11 | 2019-07-29 | Kempharm Inc | Kvetiapin zsírsav-konjugátumai, eljárás ugyanannak elkészítésére és felhasználására |
| US8088594B2 (en) | 2010-03-16 | 2012-01-03 | Saladax Biomedical Inc. | Risperidone immunoassay |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| US8623324B2 (en) | 2010-07-21 | 2014-01-07 | Aat Bioquest Inc. | Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates |
| JP5757497B2 (ja) * | 2010-10-06 | 2015-07-29 | 公立大学法人大阪府立大学 | シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット |
| WO2013024047A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| WO2013024048A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
| CN108517014A (zh) | 2012-08-21 | 2018-09-11 | 詹森药业有限公司 | 利培酮半抗原的抗体及其用途 |
| CN107043424B (zh) | 2012-08-21 | 2021-03-16 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| ES2822004T3 (es) | 2012-08-21 | 2021-04-28 | Janssen Pharmaceutica Nv | Anticuerpos contra quetiapina y uso de los mismos |
| ES2739383T3 (es) * | 2012-08-21 | 2020-01-30 | Janssen Pharmaceutica Nv | Haptenos de paliperidona |
-
2013
- 2013-08-20 ES ES13753775T patent/ES2739383T3/es active Active
- 2013-08-20 US US13/970,660 patent/US9394354B2/en not_active Expired - Fee Related
- 2013-08-20 EP EP13753775.9A patent/EP2888258B1/en active Active
- 2013-08-20 EP EP19177909.9A patent/EP3556759B1/en active Active
- 2013-08-20 ES ES19177909T patent/ES2971506T3/es active Active
- 2013-08-20 CA CA2882555A patent/CA2882555C/en active Active
- 2013-08-20 TR TR2019/11272T patent/TR201911272T4/tr unknown
- 2013-08-20 PT PT13753775T patent/PT2888258T/pt unknown
- 2013-08-20 CN CN201380054994.9A patent/CN104837838A/zh active Pending
- 2013-08-20 CN CN201910140503.1A patent/CN110003201A/zh active Pending
- 2013-08-20 WO PCT/US2013/055712 patent/WO2014031595A1/en not_active Ceased
- 2013-08-20 PL PL13753775T patent/PL2888258T3/pl unknown
- 2013-08-20 JP JP2015528570A patent/JP6286429B2/ja not_active Expired - Fee Related
- 2013-08-20 AU AU2013305930A patent/AU2013305930B2/en active Active
-
2017
- 2017-11-20 AU AU2017264978A patent/AU2017264978B2/en active Active
-
2018
- 2018-02-05 JP JP2018017796A patent/JP6491371B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3556759B1 (en) | 2023-11-29 |
| CN104837838A (zh) | 2015-08-12 |
| AU2013305930B2 (en) | 2017-08-24 |
| EP2888258B1 (en) | 2019-06-05 |
| JP6491371B2 (ja) | 2019-03-27 |
| WO2014031595A1 (en) | 2014-02-27 |
| US20140213767A1 (en) | 2014-07-31 |
| AU2017264978A1 (en) | 2017-12-07 |
| AU2017264978B2 (en) | 2019-09-12 |
| JP2018095655A (ja) | 2018-06-21 |
| HK1211934A1 (en) | 2016-06-03 |
| ES2971506T3 (es) | 2024-06-05 |
| EP3556759A1 (en) | 2019-10-23 |
| CN110003201A (zh) | 2019-07-12 |
| JP2015529197A (ja) | 2015-10-05 |
| CA2882555A1 (en) | 2014-02-27 |
| AU2013305930A1 (en) | 2015-03-05 |
| PL2888258T3 (pl) | 2019-10-31 |
| CA2882555C (en) | 2018-11-06 |
| TR201911272T4 (tr) | 2019-08-21 |
| PT2888258T (pt) | 2019-08-21 |
| EP2888258A1 (en) | 2015-07-01 |
| JP6286429B2 (ja) | 2018-02-28 |
| US9394354B2 (en) | 2016-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2739383T3 (es) | Haptenos de paliperidona | |
| ES2904838T3 (es) | Haptenos de risperidona y paliperidona | |
| ES2926662T3 (es) | Anticuerpos contra haptenos de risperidona y uso de los mismos | |
| ES2701062T3 (es) | Haptenos de olanzapina | |
| US11225527B2 (en) | Antibodies to paliperidone haptens and use thereof | |
| AU2018200435B2 (en) | Antibodies to olanzapine haptens and use thereof | |
| ES2822907T3 (es) | Haptenos de quetiapina para su uso en inmunoensayos | |
| ES2935460T3 (es) | Anticuerpos para haptenos de quetiapina y uso de los mismos | |
| ES2822914T3 (es) | Haptenos de aripiprazol y su uso en inmunoensayos | |
| HK40015705B (en) | Haptens of paliperidone | |
| HK40015705A (en) | Haptens of paliperidone | |
| HK1211934B (en) | Haptens of paliperidone | |
| HK40002082B (en) | Haptens of risperidone and paliperidone | |
| HK40002082A (en) | Haptens of risperidone and paliperidone | |
| HK1211930B (en) | Haptens of risperidone and paliperidone |